Literature DB >> 23611999

The artemisinin derivative artesunate inhibits corneal neovascularization by inducing ROS-dependent apoptosis in vascular endothelial cells.

Rui Cheng1, Cen Li, Chaoyang Li, Ling Wei, Lei Li, Yang Zhang, Yachao Yao, Xiaoqiong Gu, Weibin Cai, Zhonghan Yang, Jianxing Ma, Xia Yang, Guoquan Gao.   

Abstract

PURPOSE: Without therapeutic intervention, corneal neovascularization rapidly compromises visual acuity, and is a leading cause of blindness. Artesunate was reported to inhibit angiogenesis in tumors, although, the effects of artesunate on nontumor angiogenesis have not been investigated. This study was designed to investigate the effect of artesunate on corneal neovascularization and delineate its underlying mechanism of action.
METHODS: Rats with alkali-burned corneas were treated with artesunate for 11 days. Corneal neovascularization was evaluated by measuring the length and area of corneal vasculature in the rats. Apoptotic cells were stained with AnnexinV and propidine iodide (PI), and measured with flow cytometry analysis. Apoptosis-related and p38 mitogen-activated protein kinases (p38MAPK) signaling were evaluated by Western blot analysis.
RESULTS: Artesunate significantly inhibited corneal neovascularization and inflammation via specifically inducing apoptosis of vascular endothelial cells. In vascular endothelial cells, artesunate increased the Bax/Bcl-2 ratio, reduced mitochondrial membrane potential, stimulated release of cytochrome C, and cleavage of caspase 9 and 3, suggesting that the mitochondrial apoptotic pathway was involved. Artesunate activated p38MAPK, and specific p38MAPK inhibitors suppressed artesunate-induced apoptosis in endothelial cells. Reactive oxygen species (ROS) levels were increased by artesunate. N-acetyl-L-cysteine blocked p38MAPK activation and protected endothelial cells from artesunate-induced apoptosis. Ferrous salt increased ROS levels and elevated the cytotoxic effect of artesunate on endothelial cells, while the iron chelating agent deferoxamine decreased ROS levels and artesunate-induced apoptosis. Artesunate had no effect on expression of Fas, Fas Ligand, or caspase 8 cleavage.
CONCLUSIONS: These results suggest that artesunate induces apoptosis of endothelial cells via an iron/ROS-dependent p38MAPK-mitochondrial pathway.

Entities:  

Keywords:  apoptosis; artemisinin; corneal neovascularization; free radicals

Mesh:

Substances:

Year:  2013        PMID: 23611999      PMCID: PMC5963000          DOI: 10.1167/iovs.12-11068

Source DB:  PubMed          Journal:  Invest Ophthalmol Vis Sci        ISSN: 0146-0404            Impact factor:   4.799


  37 in total

Review 1.  Corneal neovascularization.

Authors:  J H Chang; E E Gabison; T Kato; D T Azar
Journal:  Curr Opin Ophthalmol       Date:  2001-08       Impact factor: 3.761

Review 2.  Locally administered ocular corticosteroids: benefits and risks.

Authors:  Charles N J McGhee; Simon Dean; Helen Danesh-Meyer
Journal:  Drug Saf       Date:  2002       Impact factor: 5.606

Review 3.  Factors controlling ocular angiogenesis.

Authors:  R Casey; W W Li
Journal:  Am J Ophthalmol       Date:  1997-10       Impact factor: 5.258

Review 4.  Current perspectives on the mechanism of action of artemisinins.

Authors:  Jacob Golenser; Judith H Waknine; Miriam Krugliak; Nicholas H Hunt; Georges E Grau
Journal:  Int J Parasitol       Date:  2006-09-12       Impact factor: 3.981

5.  Enhancement of cytotoxicity of artemisinins toward cancer cells by ferrous iron.

Authors:  Thomas Efferth; Achille Benakis; Marta R Romero; Maja Tomicic; Rolf Rauh; Daniel Steinbach; Ralf Häfer; Thomas Stamminger; Franz Oesch; Bernd Kaina; Manfred Marschall
Journal:  Free Radic Biol Med       Date:  2004-10-01       Impact factor: 7.376

6.  PEDF inhibits growth of retinoblastoma by anti-angiogenic activity.

Authors:  Huasheng Yang; Rui Cheng; Guoying Liu; Qinghua Zhong; Chaoyang Li; Weibin Cai; Zhonghan Yang; Jianxing Ma; Xia Yang; Guoquan Gao
Journal:  Cancer Sci       Date:  2009-08-27       Impact factor: 6.716

7.  Dihydroartemisinin induces apoptosis in HL-60 leukemia cells dependent of iron and p38 mitogen-activated protein kinase activation but independent of reactive oxygen species.

Authors:  Jin-Jian Lu; Ling-Hua Meng; Yu-Jun Cai; Qin Chen; Lin-Jiang Tong; Li-Ping Lin; Jian Ding
Journal:  Cancer Biol Ther       Date:  2008-04-04       Impact factor: 4.742

Review 8.  Angiogenesis in cancer, vascular, rheumatoid and other disease.

Authors:  J Folkman
Journal:  Nat Med       Date:  1995-01       Impact factor: 53.440

Review 9.  Qinghaosu (artemisinin): an antimalarial drug from China.

Authors:  D L Klayman
Journal:  Science       Date:  1985-05-31       Impact factor: 47.728

10.  Pharmacokinetics and pharmacodynamics of intravenous artesunate during severe malaria treatment in Ugandan adults.

Authors:  Pauline Byakika-Kibwika; Mohammed Lamorde; Jonathan Mayito; Lillian Nabukeera; Harriet Mayanja-Kizza; Elly Katabira; Warunee Hanpithakpong; Celestino Obua; Nadine Pakker; Niklas Lindegardh; Joel Tarning; Peter J de Vries; Concepta Merry
Journal:  Malar J       Date:  2012-04-27       Impact factor: 2.979

View more
  14 in total

1.  Intracellular catalase activity instead of glutathione level dominates the resistance of cells to reactive oxygen species.

Authors:  Meng-Xin Zhao; Jun-Lin Wen; Lu Wang; Xiao-Ping Wang; Tong-Sheng Chen
Journal:  Cell Stress Chaperones       Date:  2019-04-15       Impact factor: 3.667

2.  Artesunate inhibits proliferation and migration of RPE cells and TGF-β2 mediated epithelial mesenchymal transition by suppressing PI3K/AKT pathway.

Authors:  Zi-Yi Wang; Yu Zhang; Ling-Dan Wu; Jie Chen; Mei-Ling Chen; Ci-Min Chen; Qi-Hua Xu
Journal:  Int J Ophthalmol       Date:  2022-02-18       Impact factor: 1.779

Review 3.  Potential applications of artemisinins in ocular diseases.

Authors:  Bing-Wen Lu; Li-Ke Xie
Journal:  Int J Ophthalmol       Date:  2019-11-18       Impact factor: 1.779

4.  Artesunate induces cell death in human cancer cells via enhancing lysosomal function and lysosomal degradation of ferritin.

Authors:  Nai-Di Yang; Shi-Hao Tan; Shukie Ng; Yin Shi; Jing Zhou; Kevin Shyong Wei Tan; Wai-Shiu Fred Wong; Han-Ming Shen
Journal:  J Biol Chem       Date:  2014-10-10       Impact factor: 5.157

5.  Extracellular Vesicles Activate a CD36-Dependent Signaling Pathway to Inhibit Microvascular Endothelial Cell Migration and Tube Formation.

Authors:  Devi Prasadh Ramakrishnan; Rula A Hajj-Ali; Yiliang Chen; Roy L Silverstein
Journal:  Arterioscler Thromb Vasc Biol       Date:  2016-01-28       Impact factor: 8.311

6.  Melatonin Protects Against Hypoxia/Reoxygenation-Induced Dysfunction of Human Umbilical Vein Endothelial Cells Through Inhibiting Reactive Oxygen Species Generation.

Authors:  Shuo Zhao; Yueyuan Wang; Xiaoying Zhang; Lu Zheng; Bin Zhu; Shuang Yao; Ling Yang; Jun Du
Journal:  Acta Cardiol Sin       Date:  2018-09       Impact factor: 2.672

7.  Dihydroartemisinin inhibits vascular endothelial growth factor-induced endothelial cell migration by a p38 mitogen-activated protein kinase-independent pathway.

Authors:  Ling Guo; Fengyun Dong; Yinglong Hou; Weidong Cai; Xia Zhou; Ai-Ling Huang; Min Yang; Thaddeus D Allen; Ju Liu
Journal:  Exp Ther Med       Date:  2014-09-30       Impact factor: 2.447

8.  Small Molecular-Sized Artesunate Attenuates Ocular Neovascularization via VEGFR2, PKCα, and PDGFR Targets.

Authors:  Yao Zong; Yongguang Yuan; Xiaobing Qian; Zhen Huang; Wei Yang; Leilei Lin; Qishan Zheng; Yujie Li; Huining He; Qianying Gao
Journal:  Sci Rep       Date:  2016-08-02       Impact factor: 4.379

9.  CUSP9* treatment protocol for recurrent glioblastoma: aprepitant, artesunate, auranofin, captopril, celecoxib, disulfiram, itraconazole, ritonavir, sertraline augmenting continuous low dose temozolomide.

Authors:  Richard E Kast; Georg Karpel-Massler; Marc-Eric Halatsch
Journal:  Oncotarget       Date:  2014-09-30

10.  Dihydroartemisinin induces endothelial cell anoikis through the activation of the JNK signaling pathway.

Authors:  Jiao Zhang; Ling Guo; Xia Zhou; Fengyun Dong; Liqun Li; Zuowang Cheng; Yinghua Xu; Jiyong Liang; Qi Xie; Ju Liu
Journal:  Oncol Lett       Date:  2016-07-15       Impact factor: 2.967

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.